A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors

Journal of Clinical Psychiatry

Volumn 65, Issue 8, 2004, Pages 1040-1048

  Denys, Damiaan ^a,b   De Geus, Femke ^a   Van Megen, Harold J G M ^a   Westenberg, Herman G M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PLACEBO; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ADULT; AMBULATORY CARE; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; MALE; MIDDLE AGED; OBSESSIVE COMPULSIVE DISORDER; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SLEEP; TREATMENT OUTCOME; XEROSTOMIA;

ADOLESCENT; ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIBENZOTHIAZEPINES; DIZZINESS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SLEEP; TREATMENT OUTCOME; XEROSTOMIA;

EID: 4544252050     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0803     Document Type: Article

References (41)

1. Hollander E, Bienstock CA, Koran LM, et al. Refractory obsessive-compulsive disorder: state-of-the-art treatment. J Clin Psychiatry 2002; 63(suppl 6):20-29 (Pubitemid 34438946)
2. Expert Consensus Guideline Series: Treatment of Obsessive-Compulsive Disorder. J Clin Psychiatry 1997;58(suppl 4):2-72
3. McDougle CJ, Fleischmann RL, Epperson CN, et al. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 1995;56:526-528
4. Stein DJ, Bouwer C, Hawkridge S, et al. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997;58:119-122 (Pubitemid 27149253)
5. Saxena S, Wang D, Bystritsky A, et al. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996;57:303-306 (Pubitemid 26251110)
6. Pfanner C, Marazziti D, Dell'Osso L, et al. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int Clin Psychopharmacol 2000;15:297-301 (Pubitemid 30660965)
7. Weiss EL, Potenza MN, McDougle CJ, et al. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 1999;60:524-527 (Pubitemid 29413472)
8. Koran LM, Ringold AL, Elliott MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2000;61:514-517 (Pubitemid 30483423)
9. Bogetto F, Bellino S, Vaschetto P, et al. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 2000;96:91-98 (Pubitemid 30785840)
10. Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Can J Psychiatry 2001;46:356-358 (Pubitemid 32531569)
11. Crocq MA, Leclercq P, Guillon MS, et al. Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment. Eur Psychiatry 2002;17:296-297 (Pubitemid 35168010)
12. D'Amico G, Cedro C, Muscatello MR, et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:619-623 (Pubitemid 36645062)
13. Mohr N, Vythilingum B, Emsley RA, et al. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacol 2002;17:37-40 (Pubitemid 34056524)
14. Denys D, van Megen H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry 2002;63:700-703 (Pubitemid 34898434)
15. Sevincok L, Topuz A. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder. J Clin Psychopharmacol 2003;23:448-450 (Pubitemid 37128671)
16. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:794-801 (Pubitemid 30650116)
17. Hollander E, Rossi NB, Sood E, et al. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2003;6: 397-401 (Pubitemid 38146258)
18. Atmaca M, Kuloglu M, Tezcan E, et al. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002;17: 115-119 (Pubitemid 34442192)
19. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33 (Pubitemid 29001829)
20. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 1: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
22. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-223
23. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
24. Eisen JL, Phillips KA, Baer L, et al. The Brown Assessment of Beliefs Scale: reliability and validity. Am J Psychiatry 1998;155:102-108 (Pubitemid 28037556)
25. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11(suppl 3):89-95 (Pubitemid 26373761)
26. Tournel G, Houdret N, Hedouin V, et al. High-performance liquid chromatographic method to screen and quantitate seven selective serotonin reuptake inhibitors in human serum. J Chromatogr B Biomed Sci Appl 2001;761:147-158 (Pubitemid 32817104)
27. McKay D, Danyko S, Neziroglu F, et al. Factor structure of the Yale- Brown Obsessive-Compulsive Scale: a two dimensional measure. Behav Res Ther 1995;33:865-869
28. Summerfeldt LJ, Richter MA, Antony MM, et al. Symptom structure in obsessive-compulsive disorder: a confirmatory factor-analytic study. Behav Res Ther 1999;37:297-311 (Pubitemid 29119225)
29. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994;51:302-308 (Pubitemid 24127303)
30. Baxter LR, Li X, Jackson WT, et al. Adjunctive risperidone in the treatment of SSRI refractory obsessive compulsive disorder. Presented at the annual meeting of the Society of Biological Psychiatry; May 16-18, 2002; Philadelphia, Pa
31. Trethowan WH, Scott PA. Chlorpromazine in obsessive-compulsive and allied disorders. Lancet 1955;16;781-785
32. LaPorta LD. More on obsessive-compulsive symptoms and clozapine [letter]. J Clin Psychiatry 1994;55:312 (Pubitemid 24265566)
33. Koran LM, Quirk T, Lorberbaum JP, et al. Mirtazapine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 2001;21: 537-539 (Pubitemid 32937441)
34. Joel D, Doljansky J. Selective alleviation of compulsive lever-pressing in rats by D1, but not D2, blockade: possible implications for the involvement of D1 receptors in obsessive-compulsive disorder. Neuropsychopharmacology 2003;28:77-85
35. Saxena S, Brody AL, Schwartz JM, et al. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry 1998;173(suppl 35):26-37 (Pubitemid 28368348)
36. Marek GJ, Carpenter LL, McDougle CJ, et al. Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 2003;28:402-412
37. Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996;57(suppl 11):4-11 (Pubitemid 26389781)
38. Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000;23:250-262 (Pubitemid 30609659)
39. Denys D, Klompmakers AA, Westenberg HG. Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology (Berl) May 11, 2004 [electronic publication ahead of print]
40. Espejo EF. Prefrontocortical dopamine loss in rats delays long-term extinction of contextual conditioned fear, and reduces social interaction without affecting short-term social interaction memory. Neuropsychopharmacology 2003;28:490-498
41. Maina G, Albert U, Bogetto F. Relapses after discontinuation of drug associated with increased resistance to treatment in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001;16:33-38 (Pubitemid 32042839)